Adagene Inc.
ADAG
Rank in Stocks
#19812
Adagene Inc. functions as a clinical-stage biopharmaceutical organization,... Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Share Price
$2.13
Last synced: 2026-11-11
Market Cap
$96.48M
Change (1 day)
3.90%
Change (1 year)
16.39%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Adagene Inc. (ADAG)
Category
Healthcare
EPS for Adagene Inc. (ADAG)
EPS as of June 2026 TTM: $-0.47
According to Adagene Inc.'s latest financial reports, its current EPS (TTM) is $-0.47. At the end of 2025 the company had an EPS of $-0.46, an increase over its 2024 EPS of $-0.95.
EPS history for Adagene Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.47 | 2.17% |
| 2025 | $-0.46 | -51.58% |
| 2024 | $-0.95 | 72.73% |
| 2023 | $-0.55 | -76.19% |
| 2022 | $-2.31 | 0.87% |
| 2021 | $-2.29 | 288.14% |
| 2020 | $-0.59 | 20.41% |
| 2019 | $-0.49 | -67.55% |
| 2018 | $-1.51 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | 89.36% |
US
|
|
| $15.66 | -3,431.91% |
US
|
|
| $-7.07 | 1,404.26% |
US
|
|
| $-5.29 | 1,025.53% |
AU
|
|
| $12.73 | -2,808.98% |
BE
|
Questions about Adagene Inc.'s earnings per share (EPS)
What is Adagene Inc.'s earnings per share (EPS)?
Adagene Inc.'s earnings per share (EPS) over the last twelve months is $-0.47, as of Jun 2026.
What was Adagene Inc.'s earnings per share (EPS) in 2025?
In 2025, Adagene Inc.'s earnings per share (EPS) was $-0.46, compared with $-0.95 in 2024.
How has Adagene Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Adagene Inc.'s earnings per share (EPS) was highest in 2025 ($-0.46) and lowest in 2022 ($-2.31).
How does Adagene Inc.'s earnings per share (EPS) compare with similar companies?
Adagene Inc.'s earnings per share (EPS) ($-0.47) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.